These drugs, originally developed to manage diabetes, have gained significant attention for their weight loss benefits
We aimed to examine the association of glucagon-like peptidase 1 receptor agonist (GLP-1a), when compared with other glucose-lowering drugs (oGLD), with liver and non-liver complications in patients with diabetic MASLD
Sounds like a childrens book writers award
According to clinical trials, gastrointestinal symptoms typically peak during the first 48 weeks of therapy, with substantial improvement for many patients by 1216 weeks, though individual experiences vary based on the specific medication and titration schedule
This new molecule, by acting synergistically on combined systems known to be altered in T2DM [33, 34], could indeed expand the therapeutic potential of GLP-1 agonists/analogues, suggesting new scenarios in terms of improving glycemic control, weight management, and hopefully providing protection against chronic micro-macrovascular complications and not only limited to hepatic complications
Should GLP-1 users eat more protein
